Antiepileptic, structurally similar to meprobamate, q.v. Prepn: F. M. Berger, B. J. Ludwig, US 2884444 (1959 to Carter); B. J. Ludwig et al., J. Med. Chem. 12, 462 (1969). Use in treatment of epileptic seizures: R. D. Sofia, US 4978680 (1990 to Carter-Walace). HPLC determn in plasma: R. P. Remmel et al., Ther. Drug Monit. 12, 90 (1990). Pharmacology: E. A. Swinyard et al., Epilepsia 27, 27 (1986). Metabolism in animals: J. T. Yang et al., Drug Metab. Dispos. 19, 1126 (1991). Penetration of blood brain barrier: E. M. Cornford et al., Epilepsia 33, 944 (1992). Clinical pharmacokinetics: A. J. Wilensky et al., ibid. 26, 602 (1985). Clinical trial in refractory partial seizures: E. Faught et al., Neurology 43, 688 (1993). Efficacy in childhood epileptic encephalopathy (Lennox-Gastaut syndrome): F. J. Ritter et al., N. Engl. J. Med. 328, 29 (1993). Review of pharmacology, toxicology and clinical evaluation: R. D. Sofia et al., Epilepsy Res. Suppl. 3, 103-108 (1991); of clinical experience: J. M. Pellock et al., Epilepsy Res. 71, 89-101 (2006).
Anticonvulsant.
Anticonvulsant